Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

NCT06037577 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonalcoholic Steatohepatitis (NASH)
Primary Sclerosing Cholangitis (PSC)
Systemic Sclerosis (SSc)

Interventions

DRUG: CM-101
DRUG: Placebo

Sponsor

ChemomAb Ltd.